RxDoctor Payments Data

Shelly Jain, MD

Glaucoma Specialist · Columbus, OHNPI 1194928184

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. NEW World Medical,inc. accounts for 64.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $3,869 and has fallen 86.8% since, to $509 in 2025.

$11,046in general payments, 2019–2025

Across 45 payments — averaging $245.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$7K
  • Johnson & Johnson Surgical Vision, Inc.$3K
  • AbbVie$1K
  • Johnson & Johnson Vision Care, Inc.$113
  • Alcon$82
  • Sight Sciences, Inc.$36

What the payments were for

  • Consulting fees$2,60024%
  • Speaking & faculty fees$5,23847%
  • Food & beverage$3,20829%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$126,831
Medicare patients
398
Services billed
1,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost55$27,939
Alphagan PBrimonidine Tartrate30$15,092
RhopressaNetarsudil Mesylate23$13,674
RocklatanNetarsudil Mesylat/Latanoprost20$8,517
Prednisolone Acetate146$7,172
Brimonidine Tartrate86$6,530
CombiganBrimonidine Tartrate/Timolol13$4,697
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$2,960
Ketorolac Tromethamine121$2,558
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat141$2,085
Latanoprost225$1,947
Ofloxacin109$1,798
Timolol Maleate161$1,504
Pilocarpine Hcl16$814
Dorzolamide Hcl30$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$1,064$47,72798 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →